AVIR Stock Recent News

The heavy selling pressure might have exhausted for Atea Pharmaceuticals, Inc. (AVIR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Jonae Barnes - SVP, IR & Corporate Communications Jean-Pierre Sommadossi - CEO and Founder John Vavricka - CCO Janet Hammond - CDO Andrea Corcoran - CFO and Executive President, Legal Conference Call Participants Hannah Adeoye - JPMorgan Matthew Harrison - Morgan Stanley Umer Raffat - Evercore Tim Lugo - William Blair Nik Gasic - SVB Securities Operator Good afternoon, ladies and gentlemen. Welcome to the Atea Pharmaceuticals' Third Quarter 2022 Financial Results and Business Update Conference Call.

Atea Pharmaceuticals (AVIR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Monday, November 7, 2022, at 4:30 p.m. ET to report financial results for the third quarter ended September 30, 2022, and to provide a business update.

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Jonae Barnes - Senior Vice President of Investor Relations & Corporate Communications Jean-Pierre Sommadossi - Chief Executive Officer & Founder Janet Hammond - Chief Development Officer Andrea Corcoran - Chief Financial Officer & Executive President of Legal John Vavricka - Chief Commercial Officer Conference Call Participants Tim Lugo - William Blair Nik Gasic - SVB Securities Operator Good afternoon, ladies and gentlemen. Welcome to the Atea Pharmaceuticals Second Quarter 2022 Financial Results Conference Call.

BOSTON, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Monday, August 8, 2022, at 4:30 p.m. ET to report financial results for the second quarter ended June 30, 2022, and to provide a business update.

BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals, will present a corporate overview and update at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 11:00 a.m. ET.

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Q1 2022 Earnings Conference Call May 10, 2022 8:00 AM ET Company Participants Jean-Pierre Sommadossi - Founder & CEO Janet Hammond - Chief Development Officer Andrea Corcoran - CFO & EVP, Legal John Vavricka - Chief Commercial Officer Jonae Barnes - SVP, IR & Corporate Communications Conference Call Participants Hannah Colgan - JPMorgan Umer Raffat - Evercore Nik Gasic - SVB Securities Jonathan Miller - Evercore Operator Good morning, and welcome to the Atea Pharmaceuticals First Quarter 2022 Earnings Conference Call. Currently, all callers have been placed in a listen-only mode to prevent any background noise.